Novo Nordisk Stock Tumbles on Matching Industry Growth Targets
Novo Nordisk's stock took a hit on Thursday as its 2030 goals drew comparisons to those of industry peers. The Danish pharmaceutical company's shares fell 5.96% in Copenhagen trading, following its London Capital Markets Day where new CEO Mike Doustdar outlined the firm's ambitions.
The company aims for revenue growth from 2026 to 2030 at a compound annual rate that matches industry peers, which include Eli Lilly, AstraZeneca, and Johnson & Johnson. It also plans to launch more than five drugs with blockbuster potential by 2030, generate over DKK 150 billion in risk-adjusted pipeline sales by 2035, and scale oral GLP-1 manufacturing capacity tenfold.
Additionally, Novo Nordisk aims to serve more than 60 million obesity patients globally by 2030 while maintaining a stable operating margin and attractive dividend.